HOME >> MEDICINE >> NEWS
Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Tibotec Therapeutics announces initiation of the largest U.S. clinical study examining HIV treatment in treatment-experienced adult women

GRACE trial to explore gender-related differences in response to PREZISTA-based HIV therapy

Bridgewater, NJ, [Thursday, September 28, 2006] -- Tibotec Therapeutics Clinical Affairs, a division of Ortho Biotech Clinical Affairs, LLC, announced today the initiation of the largest clinical study conducted to date in treatment-experienced adult women with HIV to evaluate gender differences in response to an HIV medication.

GRACE (Gender, Race And Clinical Experience), a multi-center, open-label Phase IIIb trial, will compare gender differences in the efficacy, safety and tolerability of PREZISTA (darunavir) tablets administered with other antiretroviral agents over a 48-week treatment period. The study also will explore racial differences in treatment outcomes.

PREZISTA, co-administered with 100 mg ritonavir (PREZISTA/rtv) and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor. PREZISTA received accelerated approval based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the TMC114-C213 (POWER 1) and TMC114-C202 (POWER 2) studies. Longer-term data will be required before the FDA can consider traditional approval for PREZISTA (see the full indication and important safety information below).

There is an urgent need to conduct clinical trials designed specifically for women with HIV. The ratio of women to men among Americans diagnosed with HIV has grown substantially since the HIV epidemic first emerged.

Today, women account for almost 30 percent of new HIV diagnoses in the U.S., and rates of HIV infection are particularly high among
'"/>

Contact: Pamela Van Houten
908-541-4137
Edelman Public Relations
28-Sep-2006


Page: 1 2 3 4 5

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. AstraZeneca announces SYMBICORT is now available in the US
3. Weill Cornell Medical College announces gifts totaling $400M
4. GSK announces launch of largest ever Phase III trial in lung cancer treatment
5. Elsevier announces launch of Brain Stimulation
6. NSW Premier announces $15M for childrens cancer research
7. National Inventors Hall of Fame announces 2007 inductees
8. Emory University announces new Global Health Institute
9. BioMed Central announces Journal of Medical Case Reports
10. Wiley announces partnership with NASPGHAN and AASLD
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... and production applications. However, choosing the right method is paramount to success. Selecting ... more often in situations where multiple persons use the same equipment. Rare or ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
(Date:1/23/2017)... (PRWEB) , ... January 23, ... ... Partnership (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and ... nutritional benefits of a seafood-rich diet. These resources have been developed for ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an exotic ... the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian ... Oil and moisturizing vegetal coral to create this gentle, velvety body cream to envelop ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... a preclinical collaboration agreement with the Children,s Hospital of ... , M.D., a US key opinion leader in the mitochondrial ... ... compounds from NeuroVive,s research program, NVP015, in certain experimental disease ...
(Date:1/21/2017)... DIEGO , Jan. 20, 2017 ResMed (NYSE: ... 3B Medical ( Winter Haven, Florida ) today announced ... the parties. BMC and 3B will be permitted to sell their ... will make a one-time settlement payment to 3B to close the ... settlement did not include an admission of liability or wrongdoing by ...
(Date:1/21/2017)... & Faruqi, LLP, a leading national securities law firm, reminds ... KMPH ) of the federal securities class action lawsuit ... underwriters of the Company,s April 16, 2015 Initial Public Offering ... The lawsuit has been filed in the ... on behalf of all those who acquired KemPharm ...
Breaking Medicine Technology:
Cached News: